Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Rentschler Biopharma Announces Major Client Project for New U.S. Facility at Milford, MA Site
December 20, 2023 07:00 ET
|
Rentschler Biopharma SE
State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year LAUPHEIM, Germany and MILFORD, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Rentschler...
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
December 17, 2023 08:01 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
December 13, 2023 07:00 ET
|
EvolveImmune
Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
December 11, 2023 02:00 ET
|
Glycotope
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed...
SLRN Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
December 07, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Rentschler Biopharma SE appoints Gunnar Voss von Dahlen as Chief Financial Officer and completes Executive Board
December 07, 2023 04:00 ET
|
Rentschler Biopharma SE
LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO)...
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference
December 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
December 04, 2023 07:00 ET
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that...
Monthly information on share capital and company voting rights
December 01, 2023 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...